8305C
|
IC50 |
4.53 μM
Compound: Gemcitabine
|
Cytotoxicity against human 8305C cells after 24 hrs by MTT assay
Cytotoxicity against human 8305C cells after 24 hrs by MTT assay
|
[PMID: 24436994]
|
A2780
|
IC50 |
0.0166 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
A2780
|
IC50 |
0.035 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
A2780
|
IC50 |
0.31 μM
Compound: Gemcitabine
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
A2780
|
IC50 |
|
Growth inhibition of A2780 cells by SRB assay
Growth inhibition of A2780 cells by SRB assay
|
[PMID: 17602464]
|
A2780
|
IC50 |
|
Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole
Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
A549
|
IC50 |
< 0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
A549
|
IC50 |
> 1 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
A549
|
EC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331]
|
A549
|
IC50 |
0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
A549
|
IC50 |
0.0068 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25874330]
|
A549
|
IC50 |
0.02 μM
Compound: gemcitabine
|
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
|
[PMID: 22861499]
|
A549
|
IC50 |
0.029 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
A549
|
IC50 |
0.044 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34619466]
|
A549
|
IC50 |
0.05 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A549 cells after 3 days by MTS assay
Antiproliferative activity against human A549 cells after 3 days by MTS assay
|
[PMID: 30281308]
|
A549
|
IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytostatic activity against human A549 cells after 3 days by MTS assay
Cytostatic activity against human A549 cells after 3 days by MTS assay
|
[PMID: 30108897]
|
A549
|
IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
A549
|
IC50 |
0.09 μM
Compound: gemcitabine
|
Cytotoxicity against human A549 cells by sulforhodamine B method
Cytotoxicity against human A549 cells by sulforhodamine B method
|
[PMID: 19691349]
|
A549
|
IC50 |
0.26 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
A549
|
IC50 |
1.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
A549
|
IC50 |
13.1 μM
Compound: gemicitabine
|
Cytotoxicity against A549 cells after 72 hrs by SRB assay
Cytotoxicity against A549 cells after 72 hrs by SRB assay
|
[PMID: 17419604]
|
A549
|
IC50 |
|
Growth inhibition of A549 cells by SRB assay
Growth inhibition of A549 cells by SRB assay
|
[PMID: 17602464]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34967607]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G
|
A549
|
IC50 |
|
Growth inhibition of A549 cells by SRB assay in presence of dipyridamole
Growth inhibition of A549 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
A549
|
IC50 |
5.05 μM
Compound: 1; dFdC
|
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
ACHN
|
IC50 |
0.48 μM
Compound: Gemcitabine
|
Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay
Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
ASPC1
|
IC50 |
|
Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
ASPC1
|
IC50 |
29.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431]
|
ASPC1
|
IC50 |
35.11 μM
Compound: Gemcitabine
|
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
|
[PMID: 34838335]
|
ASPC1
|
IC50 |
|
Cytotoxicity against human Aspc-1 cells by crystal violet staining
Cytotoxicity against human Aspc-1 cells by crystal violet staining
|
[PMID: 20930123]
|
ASPC1
|
IC50 |
|
Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848]
|
B16-F10
|
IC50 |
|
Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108970]
|
BEAS-2B
|
IC50 |
0.037 μM
Compound: Gemcitabine
|
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34619466]
|
Bel-7402
|
IC50 |
0.84 μM
Compound: Gemcitabine
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
BJ
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BJ cells after 3 days by MTS assay
Antiproliferative activity against human BJ cells after 3 days by MTS assay
|
[PMID: 30281308]
|
BJ
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Cytostatic activity against human BJ cells after 3 days by MTS assay
Cytostatic activity against human BJ cells after 3 days by MTS assay
|
[PMID: 30108897]
|
BJ
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
BJ
|
IC50 |
9.88 μM
Compound: Gemcitabine
|
Cytotoxicity against human BJ cells after 3 days by MTT assay
Cytotoxicity against human BJ cells after 3 days by MTT assay
|
[PMID: 21711054]
|
BT-549
|
GI50 |
0.004 μM
Compound: gemcitabine
|
Cytotoxicity against human BT549 cells after 5 days by SRB assay
Cytotoxicity against human BT549 cells after 5 days by SRB assay
|
[PMID: 19929004]
|
BT-549
|
IC50 |
0.008 μM
Compound: Gemcitabine
|
Cytotoxicity against human BT549 cells after 3 days by MTT assay
Cytotoxicity against human BT549 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
BV-173
|
IC50 |
0.001 μM
Compound: Gemcitabine
|
Cytotoxicity against human BV173 cells after 3 days by MTT assay
Cytotoxicity against human BV173 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
BXPC-3
|
IC50 |
|
Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
|
[PMID: 32858470]
|
BXPC-3
|
IC50 |
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848]
|
BXPC-3
|
IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009]
|
BXPC-3
|
IC50 |
0.67 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay
Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay
|
[PMID: 24471998]
|
BXPC-3
|
EC50 |
|
Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay
Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay
|
[PMID: 24867590]
|
BXPC-3
|
IC50 |
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 33479633]
|
BXPC-3
|
IC50 |
2.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
BXPC-3
|
IC50 |
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
BXPC-3
|
IC50 |
25.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431]
|
BXPC-3
|
GI50 |
|
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
|
[PMID: 23094992]
|
BXPC-3
|
GI50 |
|
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
|
[PMID: 22512908]
|
BXPC-3
|
IC50 |
5.71 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 31191868]
|
BXPC-3
|
IC50 |
6 nM
Compound: Gemcitabine
|
Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay
|
[PMID: 29356532]
|
C2D cell line
|
IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926]
|
C2G cell line
|
IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926]
|
C6
|
IC50 |
0.504 μM
Compound: Gemcitabine
|
Cytotoxicity against rat C6 cells after 3 days by MTT assay
Cytotoxicity against rat C6 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
Caco-2
|
IC50 |
> 100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087]
|
Caco-2
|
GI50 |
0.18 μM
Compound: gemcitabine
|
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
|
[PMID: 18588281]
|
Caco-2
|
IC50 |
9.4 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437]
|
Calu-1
|
IC50 |
0.52 μM
Compound: Gemcitabine
|
Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
CAPAN-1
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32007666]
|
CAPAN-1
|
IC50 |
19 nM
Compound: Gemcitabine
|
Growth inhibition of human Capan1 cells after 96 hrs by SRB assay
Growth inhibition of human Capan1 cells after 96 hrs by SRB assay
|
[PMID: 29356532]
|
Capan-2
|
IC50 |
1.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay
Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
Capan-2
|
IC50 |
40.791 μM
Compound: Gemcitabine
|
Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay
Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay
|
[PMID: 30281308]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay
Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay
|
[PMID: 30108897]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
CCRF-CEM
|
IC50 |
0.069 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human CEM cells after 3 days by coulter counter analysis
Cytostatic activity against human CEM cells after 3 days by coulter counter analysis
|
[PMID: 24341356]
|
CCRF-CEM
|
IC50 |
0.086 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis
Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis
|
[PMID: 24471998]
|
CCRF-CEM
|
IC50 |
|
Growth inhibition of CEM cells by SRB assay in presence of dipyridamole
Growth inhibition of CEM cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
CCRF-CEM
|
IC50 |
|
Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole
Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
CCRF-CEM
|
IC50 |
|
Growth inhibition of CEM cells by SRB assay
Growth inhibition of CEM cells by SRB assay
|
[PMID: 17602464]
|
CCRF-CEM
|
IC50 |
|
Growth inhibition of dCK deficient CEM cells by SRB assay
Growth inhibition of dCK deficient CEM cells by SRB assay
|
[PMID: 17602464]
|
CCRF-CEM
|
IC50 |
7.6 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis
Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis
|
[PMID: 24341356]
|
CEM-DNR
|
IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay
Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay
|
[PMID: 30108897]
|
CFPAC-1
|
IC50 |
0.022 μM
Compound: Gemcitabine
|
Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782]
|
CFPAC-1
|
IC50 |
0.35 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
[PMID: 24631359]
|
CFPAC-1
|
IC50 |
0.47 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay
|
[PMID: 24631359]
|
COLO 205
|
IC50 |
0.0514 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs
Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs
|
[PMID: 18469809]
|
COLO 205
|
IC50 |
3 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
|
[PMID: 23968824]
|
COLO 320DM
|
IC50 |
|
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
|
[PMID: 23968824]
|
COLO357
|
IC50 |
|
Cytotoxicity against human Colo-357 cells by crystal violet staining
Cytotoxicity against human Colo-357 cells by crystal violet staining
|
[PMID: 20930123]
|
CT26
|
IC50 |
0.006 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse CT26 cells after 3 days by MTT assay
Cytotoxicity against mouse CT26 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
CV-1
|
IC50 |
21.9 μM
Compound: Gemcitabine
|
Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay
Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay
|
[PMID: 23489626]
|
DAN-G
|
IC50 |
|
Cytotoxicity against human DAN-G cells by crystal violet staining
Cytotoxicity against human DAN-G cells by crystal violet staining
|
[PMID: 20930123]
|
DMS-53
|
IC50 |
0.009 μM
Compound: gemcitabine
|
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
|
[PMID: 22861499]
|
DU-145
|
IC50 |
0.0356 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191]
|
DU-145
|
IC50 |
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713]
|
DU-145
|
IC50 |
3.5 nM
Compound: gemcitabine
|
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
|
[PMID: 17887663]
|
DU-145
|
IC50 |
399 nM
Compound: Gemcitabine
|
Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay
|
[PMID: 33223264]
|
EL4
|
IC50 |
0.007 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse EL4 cells after 3 days by MTT assay
Cytotoxicity against mouse EL4 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
FTC-133
|
IC50 |
3.36 μM
Compound: Gemcitabine
|
Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay
Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay
|
[PMID: 24436994]
|
HCT-116
|
IC50 |
0.005 μM
Compound: gemcitabine
|
Cytotoxicity against human HCT116 cells by sulforhodamine B method
Cytotoxicity against human HCT116 cells by sulforhodamine B method
|
[PMID: 19691349]
|
HCT-116
|
IC50 |
0.006 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
HCT-116
|
IC50 |
0.0097 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
HCT-116
|
IC50 |
0.03 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells after 3 days by MTS assay
Antiproliferative activity against human HCT116 cells after 3 days by MTS assay
|
[PMID: 30281308]
|
HCT-116
|
IC50 |
0.03 μM
Compound: Gemcitabine
|
Cytostatic activity against human HCT116 cells after 3 days by MTS assay
Cytostatic activity against human HCT116 cells after 3 days by MTS assay
|
[PMID: 30108897]
|
HCT-116
|
IC50 |
0.03 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35300092]
|
HCT-116
|
IC50 |
0.32 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay
Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
HCT-116
|
IC50 |
0.41 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay
Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay
|
[PMID: 30281308]
|
HCT-116
|
IC50 |
0.41 μM
Compound: Gemcitabine
|
Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay
Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay
|
[PMID: 30108897]
|
HCT-116
|
IC50 |
0.41 μM
Compound: Gemcitabine
|
Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
HCT-116
|
IC50 |
14.3 μM
Compound: gemzar, gemcitabine
|
Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay
Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay
|
[PMID: 18186604]
|
HCT-116
|
IC50 |
30 nM
Compound: Gemcitabine
|
Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
[PMID: 29253340]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G
|
HCT-15
|
GI50 |
0.003 μM
Compound: gemcitabine
|
Cytotoxicity against human HCT15 cells after 5 days by SRB assay
Cytotoxicity against human HCT15 cells after 5 days by SRB assay
|
[PMID: 19929004]
|
HCT-15
|
IC50 |
0.0099 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
HCT-15
|
IC50 |
0.01 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
HCT-15
|
IC50 |
11.8 μM
Compound: gemzar, gemcitabine
|
Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay
Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay
|
[PMID: 18186604]
|
HCT-8
|
IC50 |
1.74 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
HEK293
|
IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009]
|
HEL
|
CC50 |
0.0036 μM
Compound: Gemcitabine
|
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
|
[PMID: 33479570]
|
HEL
|
IC50 |
0.48 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HEL cells after 48 hrs by MTT assay
Antiproliferative activity against human HEL cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
HeLa
|
IC50 |
> 10 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
HeLa
|
IC50 |
> 10 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs
Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs
|
[PMID: 18469809]
|
HeLa
|
IC50 |
0.0099 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis
Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis
|
[PMID: 24341356]
|
HeLa
|
IC50 |
0.05 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay
Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay
|
[PMID: 22944119]
|
HeLa
|
IC50 |
0.9 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
[PMID: 24631359]
|
HeLa
|
IC50 |
10 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay
|
[PMID: 24631359]
|
HeLa
|
IC50 |
2.74 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
HeLa
|
IC50 |
3.3 μM
Compound: Gemcitabine
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296]
|
HeLa
|
IC50 |
4.12 μM
Compound: Gemcitabine
|
Cytotoxicity against human HeLa cells after 3 days by MTT assay
Cytotoxicity against human HeLa cells after 3 days by MTT assay
|
[PMID: 21711054]
|
HeLa
|
IC50 |
9.42 μM
Compound: 1; dFdC
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G
|
HepG2
|
IC50 |
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HFF-1
|
IC50 |
14.38 μM
Compound: Gemcitabine
|
Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009]
|
HPAC
|
IC50 |
0.073 μM
Compound: Gemcitabine
|
Cytotoxicity against human HPAC cells after 3 days by MTT assay
Cytotoxicity against human HPAC cells after 3 days by MTT assay
|
[PMID: 21711054]
|
HT-29
|
IC50 |
> 100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087]
|
HT-29
|
IC50 |
0.003 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191]
|
HT-29
|
GI50 |
0.03 μM
Compound: gemcitabine
|
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
|
[PMID: 18588281]
|
HT-29
|
IC50 |
0.52 μM
Compound: Gemcitabine
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 26025875]
|
HT-29
|
IC50 |
1.53 μM
Compound: Gemcitabine
|
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
HT-29
|
IC50 |
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 23968824]
|
Huh-7
|
CC50 |
|
Cytotoxicity against human HuH7 cells by MTS assay
Cytotoxicity against human HuH7 cells by MTS assay
|
[PMID: 20580554]
|
HUVEC
|
IC50 |
0.003 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay
Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay
|
[PMID: 24631359]
|
Jurkat
|
EC50 |
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331]
|
Jurkat
|
IC50 |
0.03 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
Jurkat
|
IC50 |
0.0453 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
K562
|
IC50 |
0.006 μM
Compound: Gemcitabine
|
Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay
Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
K562
|
IC50 |
0.05 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay
|
[PMID: 24631359]
|
K562
|
IC50 |
0.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human K562 cells after 3 days by MTS assay
Antiproliferative activity against human K562 cells after 3 days by MTS assay
|
[PMID: 30281308]
|
K562
|
IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytostatic activity against human K562 cells after 3 days by MTS assay
Cytostatic activity against human K562 cells after 3 days by MTS assay
|
[PMID: 30108897]
|
K562
|
IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
K562
|
IC50 |
0.11 μM
Compound: Gemcitabine
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
K562
|
GI50 |
0.32 μM
Compound: gemcitabine
|
Antitumor activity against human K562 cells after 48 hrs by MTS assay
Antitumor activity against human K562 cells after 48 hrs by MTS assay
|
[PMID: 18588281]
|
K562
|
IC50 |
0.6 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
K562
|
IC50 |
0.718 μM
Compound: Gemcitabine
|
Cytotoxicity against human K562 cells after 3 days by MTT assay
Cytotoxicity against human K562 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
K562
|
IC50 |
0.7459 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human K562 cells after 72 hrs
Antiproliferative activity against p53 deficient human K562 cells after 72 hrs
|
[PMID: 18469809]
|
KB
|
IC50 |
8.21 μM
Compound: 1; dFdC
|
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
KG-1
|
IC50 |
|
Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35300092]
|
KG-1
|
IC50 |
0.86 μM
Compound: Gemcitabine
|
Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay
Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
L02
|
IC50 |
|
Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
L02
|
IC50 |
5.43 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay
Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
L1210
|
IC50 |
0.007 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse L1210 cells after 3 days by MTT assay
Cytotoxicity against mouse L1210 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
L1210
|
IC50 |
0.013 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
|
[PMID: 24341356]
|
L1210
|
IC50 |
0.013 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis
Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis
|
[PMID: 24471998]
|
LNCaP
|
IC50 |
0.512 μM
Compound: Gemcitabine
|
Cytotoxicity against human LNCAP cells after 3 days by MTT assay
Cytotoxicity against human LNCAP cells after 3 days by MTT assay
|
[PMID: 21711054]
|
MCF-10A
|
IC50 |
> 10 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay
Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
MCF7
|
IC50 |
0.0072 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis
Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis
|
[PMID: 24341356]
|
MCF7
|
GI50 |
0.01 μM
Compound: gemcitabine
|
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 18588281]
|
MCF7
|
IC50 |
0.06 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay
|
[PMID: 22944119]
|
MCF7
|
IC50 |
0.08 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
MCF7
|
IC50 |
0.0803 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
MCF7
|
IC50 |
0.149 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
MCF7
|
IC50 |
0.15 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 26025875]
|
MCF7
|
IC50 |
0.57 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay
|
[PMID: 28075592]
|
MCF7
|
IC50 |
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633]
|
MCF7
|
IC50 |
3.28 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
MCF7
|
IC50 |
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713]
|
MCF7
|
IC50 |
6.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437]
|
MCF7
|
IC50 |
8.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay
|
[PMID: 28075592]
|
MDA-MB-231
|
IC50 |
> 10 μM
Compound: gemcitabine
|
Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 25350923]
|
MDA-MB-231
|
IC50 |
0.025 μM
Compound: gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 25350923]
|
MDA-MB-231
|
IC50 |
0.19 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296]
|
MDA-MB-231
|
IC50 |
0.245 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
MDA-MB-231
|
IC50 |
0.65 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 26025875]
|
MDA-MB-231
|
IC50 |
1.15 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
|
[PMID: 33359608]
|
MDA-MB-231
|
IC50 |
1.67 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
MDA-MB-231
|
IC50 |
11.4 nM
Compound: gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 17887663]
|
MDA-MB-231
|
IC50 |
|
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713]
|
MDA-MB-231
|
IC50 |
2.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
|
[PMID: 33139111]
|
MDA-MB-231
|
IC50 |
2.22 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359]
|
MDA-MB-231
|
IC50 |
30 nM
Compound: Gemcitabine
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
[PMID: 29253340]
|
MDA-MB-231
|
IC50 |
36.4 nM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 29795767]
|
MDA-MB-231
|
IC50 |
61.5 nM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669]
|
MDA-MB-231
|
IC50 |
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
|
[PMID: 35810950]
|
MDA-MB-231
|
IC50 |
8 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437]
|
MES-SA
|
IC50 |
0.005 μM
Compound: Gemcitabine
|
Cytotoxicity against human MES-SA cells after 3 days by MTT assay
Cytotoxicity against human MES-SA cells after 3 days by MTT assay
|
[PMID: 21711054]
|
MES-SA/Dx5
|
IC50 |
0.0092 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191]
|
MIA PaCa-2
|
EC50 |
0.0015 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 28105281]
|
MIA PaCa-2
|
IC50 |
0.016 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782]
|
MIA PaCa-2
|
IC50 |
0.06 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay
|
[PMID: 22944119]
|
MIA PaCa-2
|
IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009]
|
MIA PaCa-2
|
IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
[PMID: 29328656]
|
MIA PaCa-2
|
IC50 |
0.12 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay
Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay
|
[PMID: 29471119]
|
MIA PaCa-2
|
IC50 |
0.23 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
|
[PMID: 33359608]
|
MIA PaCa-2
|
IC50 |
0.36 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359]
|
MIA PaCa-2
|
IC50 |
0.6 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296]
|
MIA PaCa-2
|
IC50 |
1.04 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay
Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay
|
[PMID: 24471998]
|
MIA PaCa-2
|
EC50 |
|
Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay
Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay
|
[PMID: 24867590]
|
MIA PaCa-2
|
IC50 |
3.3 μM
Compound: Gemcitabine
|
Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
[PMID: 29328656]
|
MIA PaCa-2
|
GI50 |
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
|
[PMID: 23094992]
|
MIA PaCa-2
|
GI50 |
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
|
[PMID: 22512908]
|
MKN-28
|
IC50 |
> 100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087]
|
MRC5
|
IC50 |
< 0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
MRC5
|
IC50 |
< 0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
MRC5
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MRC5 cells after 3 days by MTS assay
Antiproliferative activity against human MRC5 cells after 3 days by MTS assay
|
[PMID: 30281308]
|
MRC5
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
MRC5
|
IC50 |
0.0063 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay
Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay
|
[PMID: 25874330]
|
MRC5
|
IC50 |
0.0068 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
MRC5
|
IC50 |
0.0216 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
MRC5
|
IC50 |
35.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431]
|
MRC5
|
IC50 |
80 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437]
|
NCI-H146
|
IC50 |
2.78 μM
Compound: Gemcitabine
|
Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay
Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
NCI-H1975
|
IC50 |
|
Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay
Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
NCI-H23
|
GI50 |
0.002 μM
Compound: gemcitabine
|
Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay
Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay
|
[PMID: 19929004]
|
NCI-H460
|
IC50 |
0.0078 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191]
|
NCI-H460
|
IC50 |
0.23 μM
Compound: Gemcitabine
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
NCI-H460
|
IC50 |
|
Growth inhibition of H460 cells by SRB assay
Growth inhibition of H460 cells by SRB assay
|
[PMID: 17602464]
|
NCI-H460
|
IC50 |
|
Growth inhibition of H460 cells by SRB assay in presence of dipyridamole
Growth inhibition of H460 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
NHDF
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
NHDF
|
IC50 |
0.0221 μM
Compound: Gemcitabine
|
Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
NHDF
|
IC50 |
19.45 μM
Compound: 1; dFdC
|
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
OVCAR-8
|
IC50 |
0.0026 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
OVCAR-8
|
IC50 |
0.003 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
P388D1
|
IC50 |
0.019 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay
Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
PANC-1
|
IC50 |
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay
|
[PMID: 35969895]
|
PANC-1
|
EC50 |
> 2000 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole
|
[PMID: 24471998]
|
PANC-1
|
IC50 |
> 50 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 23489626]
|
PANC-1
|
IC50 |
> 500 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
|
[PMID: 32920143]
|
PANC-1
|
IC50 |
0.022 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 32736230]
|
PANC-1
|
IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay
Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146]
|
PANC-1
|
IC50 |
0.15 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32007666]
|
PANC-1
|
IC50 |
|
Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay
Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay
|
[PMID: 31026162]
|
PANC-1
|
IC50 |
|
Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay
Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay
|
[PMID: 31026162]
|
PANC-1
|
IC50 |
0.2 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009]
|
PANC-1
|
IC50 |
0.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
|
[PMID: 29656202]
|
PANC-1
|
IC50 |
|
Cytotoxicity against human PANC1 cells by crystal violet staining
Cytotoxicity against human PANC1 cells by crystal violet staining
|
[PMID: 20930123]
|
PANC-1
|
IC50 |
1.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
|
[PMID: 29656202]
|
PANC-1
|
IC50 |
10.988 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782]
|
PANC-1
|
IC50 |
30 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431]
|
PANC-1
|
IC50 |
|
Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
PANC-1
|
IC50 |
4.2 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437]
|
PANC-1
|
IC50 |
5.6 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
PANC-1
|
GI50 |
5.8 μM
Compound: Gemcitabine
|
Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay
Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay
|
[PMID: 28495081]
|
PANC-1
|
IC50 |
5.9 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
|
[PMID: 31967821]
|
PANC-1
|
EC50 |
611 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole
|
[PMID: 24471998]
|
PANC-1
|
IC50 |
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848]
|
PaTu 8988t
|
IC50 |
|
Cytotoxicity against human Patu-T cells by crystal violet staining
Cytotoxicity against human Patu-T cells by crystal violet staining
|
[PMID: 20930123]
|
PC-3
|
IC50 |
0.0026 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
PC-3
|
IC50 |
0.003 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
PC-3
|
GI50 |
0.006 μM
Compound: gemcitabine
|
Cytotoxicity against human PC3 cells after 5 days by SRB assay
Cytotoxicity against human PC3 cells after 5 days by SRB assay
|
[PMID: 19929004]
|
PC-3
|
IC50 |
0.04 μM
Compound: gemcitabine
|
Cytotoxicity against human PC3 cells by sulforhodamine B method
Cytotoxicity against human PC3 cells by sulforhodamine B method
|
[PMID: 19691349]
|
PC-3
|
EC50 |
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331]
|
PC-3
|
IC50 |
0.22 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
PC-3
|
IC50 |
|
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713]
|
PC-3
|
IC50 |
546 nM
Compound: Gemcitabine
|
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
|
[PMID: 33223264]
|
PC-3
|
IC50 |
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633]
|
PLC-PRF-5
|
IC50 |
1.53 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay
Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
PSN1
|
IC50 |
|
Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
|
[PMID: 32858470]
|
Ramos
|
IC50 |
|
Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay
Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay
|
[PMID: 28576633]
|
Ramos
|
EC50 |
|
Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331]
|
RT-112
|
EC50 |
1.4 nM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine
|
[PMID: 24471998]
|
RT-112
|
EC50 |
104.9 nM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine
|
[PMID: 24471998]
|
SF-268
|
IC50 |
0.01 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
SF-268
|
IC50 |
0.0103 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs
Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs
|
[PMID: 18469809]
|
SF-539
|
IC50 |
0.0198 μM
Compound: Gemcitabine
|
Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
SF-539
|
IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
SGC-7901
|
IC50 |
|
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G
|
SK-MEL-2
|
IC50 |
7.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
SK-N-AS
|
IC50 |
1.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay
Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay
|
[PMID: 21711054]
|
SK-OV-3
|
IC50 |
> 10 μM
Compound: Gemcitabine
|
Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
|
[PMID: 21711054]
|
SMMC-7721
|
IC50 |
1.4 μM
Compound: Gemcitabine
|
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 33444848]
|
SW1573
|
IC50 |
|
Growth inhibition of SW1573 cells by SRB assay
Growth inhibition of SW1573 cells by SRB assay
|
[PMID: 17602464]
|
SW1573
|
IC50 |
|
Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole
Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464]
|
SW1573
|
IC50 |
8.3 μM
Compound: gemicitabine
|
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
|
[PMID: 17419604]
|
SW1990
|
IC50 |
1.2 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay
Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay
|
[PMID: 19362474]
|
SW1990
|
IC50 |
2.3 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27966950]
|
SW1990
|
IC50 |
25.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431]
|
SW1990
|
IC50 |
40.19 μM
Compound: Gemcitabine
|
Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
|
[PMID: 34838335]
|
SW480
|
IC50 |
0.0136 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
SW480
|
IC50 |
1.7 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
SW-620
|
IC50 |
|
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G
|
T-24
|
IC50 |
< 0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
T-24
|
IC50 |
< 0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
T-24
|
IC50 |
0.0069 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells after 48 hrs by SRB assay
Cytotoxicity against human T24 cells after 48 hrs by SRB assay
|
[PMID: 25874330]
|
T-24
|
IC50 |
0.017 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
T-24
|
IC50 |
0.018 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330]
|
T-24
|
IC50 |
|
Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay
|
[PMID: 35434624]
|
T-24
|
IC50 |
|
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 32827851]
|
TRAMP-C1A
|
IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926]
|
TRAMP-C2H
|
IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay
Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay
|
[PMID: 27010926]
|
U-266
|
IC50 |
0.22 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
U2OS
|
IC50 |
0.0907 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809]
|
U2OS
|
IC50 |
0.18 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740]
|
U2OS
|
IC50 |
0.18 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells after 3 days by MTS assay
Antiproliferative activity against human U2OS cells after 3 days by MTS assay
|
[PMID: 30281308]
|
U2OS
|
IC50 |
0.18 μM
Compound: Gemcitabine
|
Cytostatic activity against human U2OS cells after 3 days by MTS assay
Cytostatic activity against human U2OS cells after 3 days by MTS assay
|
[PMID: 30108897]
|
U2OS
|
IC50 |
0.18 μM
Compound: Gemcitabine
|
Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790]
|
U373-MAGI
|
EC50 |
27.5 nM
Compound: dFdC, Gem, Gemcitabine
|
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
|
[PMID: 24120088]
|
U373-MAGI
|
CC50 |
284 μM
Compound: Gemcitabine
|
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
|
[PMID: 27117260]
|
U373-MAGI
|
EC50 |
53.5 μM
Compound: Gemcitabine
|
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas
|
[PMID: 27117260]
|
U373-MAGI
|
CC50 |
62 μM
Compound: dFdC, Gem, Gemcitabine
|
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
|
[PMID: 24120088]
|
U-87MG ATCC
|
EC50 |
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331]
|
U-87MG ATCC
|
IC50 |
1.49 μM
Compound: Gemcitabine
|
Cytotoxicity against human U87MG cells after 3 days by MTT assay
Cytotoxicity against human U87MG cells after 3 days by MTT assay
|
[PMID: 21711054]
|
U-87MG ATCC
|
IC50 |
5.21 μM
Compound: 1; dFdC
|
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
U-87MG ATCC
|
IC50 |
8.2 nM
Compound: gem; dFdC
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay
|
[PMID: 31469566]
|
U-937
|
IC50 |
0.07 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U937 cells after 48 hrs by MTT assay
Antiproliferative activity against human U937 cells after 48 hrs by MTT assay
|
[PMID: 27670098]
|
Vero
|
CC50 |
0.0043 μM
Compound: Gemcitabine
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis
|
[PMID: 33479570]
|
WM 266-4
|
IC50 |
|
Inhibition of cell growth in human WM266-4 cells measured after 24 hrs
Inhibition of cell growth in human WM266-4 cells measured after 24 hrs
|
[PMID: 34967607]
|